Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines. (26th September 2013)

• Record Type: Journal Article
• Authors: Fralick, Michael; Ray, Monali; Fung, Christina; Booth, Christopher M.; Mallick, Ranjeeta; Clemons, Mark J.
• Is Part Of: Oncologist. Volume 18:Number 11(2013)
• Page Start: 1174
• Page End: 1179
• Publication Date: 2013-09-26
• Subjects: Media -- Health services -- Bevacizumab -- Breast cancer -- Drug funding; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2013-0160
• Languages: English
• ISSNs: 1083-7159

Abstract

Learning Objectives: Summarize findings regarding the media's portrayal of bevacizumab with each phase of therapeutic development. Identify media sources of information about bevacizumab in each phase of therapeutic development. Abstract : Introduction: On February 22, 2008, the Food and Drug Administration granted accelerated approval for the use of bevacizumab (Avastin) in metastatic breast cancer. Based on subsequent clinical trials, this approval was revoked on November 18, 2011. In this study, we categorize and analyze the newspaper reports related to bevacizumab's use in advanced breast cancer. Methods: Using the Factiva media database, we reviewed all newspaper reports published in North America from January 4, 2002, to January 4, 2013, containing the words "breast cancer" and "Avastin, " or "bevacizumab." Articles were classified as pre‐approval (January 4, 2002–February 21, 2008), approval (February 22, 2008–November 17, 2011), or post‐approval loss (November 18, 2011–January 4, 2013). Information regarding benefits, side effects, costs, interviewees, and article tone and theme were abstracted from each article by two independent reviewers. Differences among the three study phases were compared using the chi square analysis. Results: A total of 359 articles met study inclusion criteria. The number of reports having a positive headline tone and/or positive article tone declined with each study period. The proportion of articles discussing side effects and financial costs increased, whereas those discussing efficacy decreased with each study period. Drug representatives were most likely to be quoted in newspaper articles prior to bevacizumab's approval. Conclusion: Media reports are a common source of medical information for patients, practitioners, and policy makers. We observed substantial fluidity of media reports over time. Abstract : In February 2008, the U.S. Food and Drug Administration granted accelerated approval for the use of bevacizumab in metastatic breast cancer; however, approval was revoked in November 2011. We sought to categorize and analyze the newspaper reports related to bevacizumab's use in advanced breast cancer. Media reports are a common source of medical information, and we observed substantial fluidity of media reports over time. Abstract : 摘要 学习目标 分析在贝伐珠单抗的各个研发阶段中，媒体对贝伐珠单抗的描述有何改变，然后对这些分析结果进行总结。 确认在贝伐珠单抗的各个研发阶段中，媒体所引用的有关贝伐珠单抗的信息来源于哪里。 简介。 2008 年 2 月 22 日，美国食品及药品管理局同意对贝伐珠单抗（阿瓦斯汀）的转移性乳腺癌适应症实行加速批准程序。然而根据后续的临床试验结果，这一核准决定却在 2011 年 11 月 18 日被撤销。贝伐珠单抗在晚期乳腺癌中的使用获得了大量新闻报道，本研究即对这些报道进行了分类和分析。 方法。 借助 Factiva 媒体数据库，我们搜索出了北美在 2002 年 1 月 4 日至 2013 年 1 月 4 日期间所刊登的所有包含"乳腺癌"和"阿瓦斯汀"或"贝伐珠单抗"的新闻报道，并对他们进行了分析。我们将这些文章分为批准前(2002.01.04‐2008.02.21)、批准后 (2008.02.22‐2011.11.17) 以及批准撤销后 (2011.11.18‐2013.01.04) 三个阶段。我们请两位独立评审员从每篇文章中摘出有关贝伐珠单抗的益处、副作用、成本、被访者以及文章基调和主题的信息，然后使用卡方检验法对这三个研发阶段的媒体报道进行了比较。 结果。 共有 359 篇文章符合本研究的纳入标准。那些标题和/或正文为正面语调的报道，其数量随着研发阶段的进展而下降。讨论副作用和经济成本的文章所占的比例随着研发阶段的进展而升高，讨论疗效的文章所占的比例则随着研发阶段的进展而降低。医药代表的话在贝伐珠单抗获批之前所刊登的文章中被引用的几率最高。 结论。 媒体报道是患者、医疗从业者和政策制定者获取医疗信息的常见来源。我们观察到媒体报道随着时间的变化而表现出了极大的易变性。 The Oncologist 2013;18:1174–1179